On Tuesday, Idexx Laboratories, Inc. (NASDAQ: IDXX) opened lower -0.36% from the last session, before settling in for the closing price of $449.44. Price fluctuations for IDXX have ranged from $372.50 to $583.39 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 10.69%. Company’s average yearly earnings per share was noted 4.34% at the time writing. With a float of $81.43 million, this company’s outstanding shares have now reached $83.03 million.
Let’s determine the extent of company efficiency that accounts for 11000 employees. In terms of profitability, gross margin is 60.45%, operating margin of 28.67%, and the pretax margin is 28.06%.
Idexx Laboratories, Inc. (IDXX) Insider Activity
A key investor’s attitude towards the stock of the Diagnostics & Research industry is another important factor to consider. The insider ownership of Idexx Laboratories, Inc. is 1.07%, while institutional ownership is 93.11%. The most recent insider transaction that took place on Sep 06 ’24, was worth 234,686. In this transaction Director of this company sold 500 shares at a rate of $469.37, taking the stock ownership to the 0 shares. Before that another transaction happened on Sep 06 ’24, when Company’s Director proposed sale 500 for $469.78, making the entire transaction worth $234,890.
Idexx Laboratories, Inc. (IDXX) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around 4.34% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.00% during the next five years compared to 18.76% growth over the previous five years of trading.
Idexx Laboratories, Inc. (NASDAQ: IDXX) Trading Performance Indicators
Check out the current performance indicators for Idexx Laboratories, Inc. (IDXX). In the past quarter, the stock posted a quick ratio of 0.98. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.74. Likewise, its price to free cash flow for the trailing twelve months is 43.94.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 10.09, a number that is poised to hit 2.68 in the next quarter and is forecasted to reach 12.29 in one year’s time.
Technical Analysis of Idexx Laboratories, Inc. (IDXX)
Looking closely at Idexx Laboratories, Inc. (NASDAQ: IDXX), its last 5-days average volume was 0.6 million, which is a jump from its year-to-date volume of 0.48 million. As of the previous 9 days, the stock’s Stochastic %D was 11.28%. Additionally, its Average True Range was 10.35.
During the past 100 days, Idexx Laboratories, Inc.’s (IDXX) raw stochastic average was set at 5.30%, which indicates a significant decrease from 10.60% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 13.83% in the past 14 days, which was lower than the 22.68% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $483.00, while its 200-day Moving Average is $504.87. However, in the short run, Idexx Laboratories, Inc.’s stock first resistance to watch stands at $452.45. Second resistance stands at $457.08. The third major resistance level sits at $461.70. If the price goes on to break the first support level at $443.20, it is likely to go to the next support level at $438.58. Should the price break the second support level, the third support level stands at $433.95.
Idexx Laboratories, Inc. (NASDAQ: IDXX) Key Stats
There are currently 82,306K shares outstanding in the company with a market cap of 36.86 billion. Presently, the company’s annual sales total 3,661 M according to its annual income of 845,040 K. Last quarter, the company’s sales amounted to 1,004 M and its income totaled 203,300 K.
